The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Display Library Technologies and Affiliated Services Market by Type of Technology (Phage Display, Yeast Display and Others), Type of Molecule (Antibodies, Peptides and Others), and Key Geographical Regions (North America, Europe and Asia-Pacific), Industry Trends and Global Forecasts: 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    June 2021

  • Pages
    205

  • View Count
    648

Example Insights

Display-Library-Technologies-and-Affiliated-Services-Market-Context Display-Library-Technologies-and-Affiliated-Services-Market-Overall-Market-Landscape 	Display-Library-Technologies-and-Affiliated-Services-Market-Distribution-by-Type-of-Technology
Display-Library-Technologies-and-Affiliated-Services-Market-Partnerships-and-Collaborations Display-Library-Technologies-and-Affiliated-Services-Market-Publication-Analysis Display-Library-Technologies-and-Affiliated-Services-Market-Intellectual-Property-Landscape
Display-Library-Technologies-and-Affiliated-Services-Market-List-of-Approved-Biologics Display-Library-Technologies-and-Affiliated-Services-Market-Opportunity  

 

Overview

Biologics are one of the fastest growing classes of therapeutics in the pharmaceutical industry. However, the development of such large molecule drugs is inherently complex, involving elaborate target selection and validation, hit generation, lead selection / optimization and characterization protocols. Of the aforementioned steps, hit (potential drug candidates against validated biological targets) generation is a highly resource-intensive process. In fact, it is estimated that an average of 18 months is spent in generating hits against a validated target. Additionally, there is an approximate 25% chance of failure in the hit generation to lead identification phase of drug discovery. Over time, a variety of methods / approaches have been developed for the generation of viable therapeutic leads; these include the hybridoma technology, B-cell cloning, transgenic animal-based techniques, in vitro display methods (using phages, ribosomes, mRNA, and cDNA) and cell surface display methods (involving mammalian, yeast, and bacterial cells). Despite being responsible for the development of several successful therapies, the hybridoma and B-cell based hit generation techniques are limited in several aspects; for instance, drugs / drug candidates developed using the aforementioned technologies are often highly immunogenic, and developers also find it difficult to develop and produce stable molecules with noteworthy affinities for their respective targets. As a result, innovator companies have demonstrated a preference for some of the relatively newer hit generation methods, which involve the use of display-libraries. 

In modern medical research, display libraries have been successfully employed for the generation of various novel therapeutics and offer certain advantages over conventional drug screening methods, including (but not limited to) the ability to facilitate large-scale, high throughput screening, incorporation of greater diversity in viable lead identification, and eliminating the threat of possible immune response to pharmacological candidates identified through this approach. Out of the available display technologies, those based on phages are the most popular, primarily owing to the simplicity of the selection method they offer and the fact that they can be used to generate hits against several complex antigens. In fact, we observed that more than 15 biologics (including antibodies, proteins and peptides) that were discovered using phage display technologies, have already been approved by the USFDA; prominent examples include Humira®, Cyramza® and Benlysta®. Further, according to various sources, around 70 display library-derived antibodies have entered clinical studies. There are many other versatile display technologies, namely yeast display, mammalian display, ribosomal display, bacterial display, mRNA display and cDNA display, which have their own benefits and have gained commendable recognition among innovators in the biopharmaceutical industry, in recent years. The growing interest in using display libraries is reflected in the recent increase in partnership activity, especially between companies that offer this technology / related services and drug developers. In summary, display technologies have enabled notable evolutionary changes in the drug discovery paradigm; we are led to believe that the display library technologies market is likely to witness healthy growth in the coming years.

Scope of the Report

The ‘Display Library Technologies and Affiliated Services Market, 2021-2030’ report features an extensive study of the current landscape of display library technologies and services market and the future opportunities associated with such technologies. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the report features:

  • A detailed assessment of the overall landscape of the display library technologies and affiliated services market, highlighting the services and technologies provided by industry players along with the information on year of establishment, company size, location of headquarters, type of company, display library expertise, type of molecules (antibodies, peptides, proteins and others), type and format of antibodies generated, library size / complexity, and other services offered. 
  • Elaborate profiles of the companies offering display library technologies. Each profile features a brief overview of the company, proprietary technology(s), recent developments and an informed future outlook.
  • A case study featuring a list of biologics discovered using phage display method along with analyses, based on a number of relevant parameters, such as first launch year, target gene / antigen, disease indication and target therapeutic area, revenues (2020) generated and brief profiles.
  • An analysis of the partnerships that have been established in this domain since 2017, covering R&D collaborations, licensing agreements, mergers and acquisitions, and other relevant deals.
  • A detailed review of close to 2,000 peer-reviewed, scientific articles related to research on display libraries, which have been published between 2017 and March 2021. It also discusses the trends across year of publication, focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).
  • An in-depth analysis of the patents filed / granted for display library technologies, since 2017, based on the various parameters associated with the patents, including patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, highlighting the leading players. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

One of the key objectives of the report was to estimate the existing market size and future opportunities within the display library services market, for the next decade. Based on parameters, such as size of the overall antibody and peptide discovery services market, R&D expenses incurred in hit generation step of drug discovery and several others, we have provided an informed estimate of the likely evolution of the display library services market (focus on hit generation) in the mid to long term, for the time period 2021-2030. The report also features the likely distribution of the opportunity across [A] type of display library technology (phage display, yeast display and others), [B] type of molecule (antibodies, peptides and others), [C] geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Andrew Bradbury (CSO / Founder, Specifica) and Ken Sharples (CEO / Founder, Specifica)
  • Thomas Schirrmann (CEO / General Manager, YUMAB)
  • Benjamin J. Doranz (President and CEO, Integral Molecular)
  • Debby Kruijsen (General Manager, ImmunoPrecise Antibodies, Europe)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players offering display library technologies and affiliated services?
  • What are the recent developments and emerging trends in the display library technologies domain?
  • How has the intellectual property landscape in this market evolved over the years?
  • What factors are likely to influence the evolution of this upcoming market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the display library technologies and services market in the mid to long term.

Chapter 3 provides an overview of display library technologies, including information on their types, phage display, bacterial display, yeast display, mammalian display, ribosome display, mRNA display, cDNA display. In addition, it discusses the various advantages, applications and future prospects of display technologies.

Chapter 4 provides a general overview of the current market landscape of over 70 phage display library technologies and service providers. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of company (service provider, technology provider or both), type of molecule generated, type and format of antibodies generated, library size / complexity, source of genetic material (basis for candidate) and other services offered. In addition, the chapter also includes a list of companies that offer drug discovery platforms.

Chapter 5 provides a general overview of the current market landscape of more than 20 service and technology providers having expertise across other display technologies (yeast display, mammalian display, ribosomal display, bacterial display, mRNA display and cDNA display). It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of company (service provider, technology provider or both), type of molecule generated (antibodies, peptides, proteins and others), type and format of antibodies generated, library size / complexity, source of genetic material (basis for candidate) and other services offered. In addition, the chapter also includes a list of companies that offer drug discovery platforms.

Chapter 6 provides detailed profiles of the stakeholders that are actively engaged in providing display library technologies and services to pharmaceutical companies and research institutions. Each profile features a brief overview of the company, details on proprietary technology(s), recent developments and an informed future outlook.

Chapter 7 is a case study featuring a list of biologics discovered using phage display method along with analyses, based on a number of relevant parameters, such as first launch year, target gene / antigen, disease indication and target therapeutic area, revenues (2020) generated and brief profiles.

Chapter 8 features an in-depth analysis on the various partnerships inked between the players in this market, during the period, 2017-2021 (till March), covering R&D collaborations, licensing agreements, mergers and acquisitions, and other relevant deals.

Chapter 9 provides information on certain recent publications that we came across during our research on display library technologies. This chapter features a detailed analysis the key prevalent trends associated with these publications, including information on year of publication, focus area (type of technology / molecule), popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal) to offer better insights on the emerging trends in this area.

Chapter 10 provides an overview of the various patents that have been filed / granted in relation to display library technologies. It also features a detailed analysis, highlighting the prevalent trends related to publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry players (in terms of number of patents filed). In addition, the chapter also features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. For the purpose of this analysis, we have taken into consideration patents that have been filed / granted since 2017.

Chapter 11 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. The overall display library technologies and affiliated services market was estimated on the basis of cost incurred by hit generation services within the discovery phase of antibodies and peptides. The chapter also features the likely distribution of the opportunity across [A] type of display library technology (phage display, yeast display and others), [B] type of molecule (antibodies, peptides and others), [C] geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 13 is a collection of executive insight(s) of the discussion(s) that were held with key stakeholder(s) in this market.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which provides a list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Display Library Technologies 
3.3. Types of Display Libraries

3.3.1. In Vitro Display Technologies
3.3.1.1. Phage Display
3.3.1.1.1. Classification of Phage Display Libraries
3.3.1.1.2. Applications of Phage Display Libraries
3.3.1.2. Ribosomal Display Library
3.3.1.3. mRNA Display Library
3.3.1.4. cDNA Display Library

3.3.2. Cell Surface Display Technologies
3.3.2.1. Bacterial Display Library
3.3.2.2. Yeast Display Library
3.3.2.3. Mammalian Cell-based Display Libraries

3.4. Applications of Display Libraries
3.5. Future Perspectives

4. MARKET LANDSCAPE: LIBRARY-BASED DISPLAY TECHNOLOGIES AND SERVICES (FOCUS ON PHAGE DISPLAY)
4.1. Chapter Overview
4.2. Display Library Technologies and Affiliated Services (Focus on Phage Display): Overall Market Landscape
4.2.1. Analysis by Type of Molecule Discovered
4.2.2. Analysis by Type of Antibodies Generated
4.2.3. Analysis by Type of Library
4.2.4. Analysis by Library Size / Complexity
4.2.5. Analysis by Source Organism
4.2.6. Analysis by Types of Services Offered

4.3. Display Library Technologies and Affiliated Services (Focus on Phage Display): Key Industry Players
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Type of Company
4.3.4 Analysis by Location of Headquarters

5. MARKET LANDSCAPE: DISPLAY LIBRARY TECHNOLOGIES AND AFFILIATED SERVICES (FOCUS ON OTHER DISPLAY TECHNOLOGIES)
5.1. Chapter Overview
5.2. Display Library Technologies and Affiliated Services (Focus on Other Display Technologies): Overall Market Landscape
5.2.1 Analysis by Type of Technology
5.2.2. Analysis by Type of Molecule Discovered
5.2.3. Analysis by Type of Antibodies Generated
5.2.4. Analysis by Type of Library
5.2.5. Analysis by Library Size / Complexity
5.2.6. Analysis by Source Organism
5.2.7. Analysis by Types of Services Offered

5.3. Display Library Technologies and Affiliated Services (Focus on Other Display Technologies): Key Industry Players
5.3.1 Analysis by Year of Establishment
5.3.2 Analysis by Company Size
5.3.3 Analysis by Type of Company
5.3.4 Analysis by Location of Headquarters

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Abzena
6.2.1. Company Overview
6.2.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Creative Biolabs
6.3.1. Company overview
6.3.2. Technology Portfolio
6.3.3. Service Portfolio
6.3.4. Recent Developments and Future Outlook

6.4. Distributed Bio (Subsidiary of Charles River)
6.4.1. Company Overview
6.4.2. Technology Portfolio
6.4.2.1. Recent Developments and Future Outlook

6.5. ImmunoPrecise Antibodies
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Service Portfolio
6.5.4. Recent Developments and Future Outlook

6.6. IONTAS
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Service Portfolio
6.6.4. Recent Developments and Future Outlook

6.7. LakePharma
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Service Portfolio
6.7.4. Recent Developments and Future Outlook

6.8. Leading Biology
6.8.1. Company overview
6.8.2. Technology Portfolio
6.8.3. Service Portfolio
6.8.4. Recent Developments and Future Outlook

6.9. Sino Biological
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Service Portfolio
6.9.4. Recent Developments and Future Outlook

6.10. XOMA
6.10.1. Company Overview
6.10.2. Technology Portfolio
6.10.3. Recent Developments and Future Outlook

7. CASE STUDY: BIOLOGICS DISCOVERED USING PHAGE DISPLAY METHOD
7.1. Chapter Overview
7.2. Biologics Discovered Using the Phage Display Method
7.2.1. Analysis by Year of Launch
7.2.2. Analysis by Target Antigen / Gene
7.2.3. Analysis by Target Disease Indication and Therapeutic Area
7.2.4. Analysis by Revenues Generated (2020)

7.3. Biologics Discovered Using Phage Display Method: Brief Profiles
7.3.1. Humira® (Adalimumab)
7.3.1.1. Drug Overview
7.3.1.2. Discovery Process and Method

7.3.2. Tremfya® (Guselkumab)
7.3.2.1. Drug Overview
7.3.2.2. Discovery Process and Method

7.3.3. Takhzyro® (Lanadelumab)
7.3.3.1. Drug Overview
7.3.3.2. Discovery Process and Method

7.3.4. Xyntha® 
7.3.4.1. Drug Overview
7.3.4.2. Discovery Process and Method

7.3.5. Portrazza™ (Necitumumab)
7.3.5.1. Drug Overview
7.3.5.2. Discovery Process and Method

7.4. Concluding Remarks

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Display Library Technologies and Affiliated Services: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Focus of Partnership (Type of Molecule)
8.3.4. Analysis by Focus of Partnership (Target Therapeutic Area)
8.3.5. Analysis by Type of Partner
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Analysis by Geography
8.3.7.1. Intercontinental and Intracontinental Agreements

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Analysis by Year of Publication
9.4. Analysis by Focus Area (Type of Technology)
9.5. Analysis by Focus Area (Type of Molecule)
9.6. Word Cloud: Analysis of Study Titles
9.7. Key Journals: Analysis by Number of Publications

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Display Library Technologies: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geography
10.3.3. Analysis by CPC Symbols
10.3.4. Emerging Focus Areas (Word Cloud)
10.3.5. Analysis by Type of Applicant
10.3.6. Leading Players: Analysis by Number of Patents
10.3.7 Leading Players: International Patents
10.3.8. Display Library Technologies: Patent Valuation Analysis

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key assumptions and Forecast Methodology 
11.3. Global Display Library Technologies Market (Focus on Hit Generation Services), 2021-2030
11.4. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Type of Display Library Technology
11.5. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Type of Molecule
11.6. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Geography

11.6.1. Display Library Technologies and Affiliated Services Market Opportunity in North America Across Key Market Segments, 2021-2030
11.6.1.1 Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Distribution by Type of Technology
11.6.1.1.1 Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Phage Display Technology
11.6.1.1.2. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Yeast Display Technology
11.6.1.1.3. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Other Display Technologies
11.6.1.2. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Distribution by Type of Molecule
11.6.1.2.1. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Antibodies
11.6.1.2.2. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Peptides
11.6.1.2.3. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Other Molecules

11.6.2. Display Library Technologies and Affiliated Services Market Opportunity in Europe Across Key Market Segments, 2021-2030
11.6.2.1 Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Distribution by Type of Technology
11.6.2.1.1 Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Phage Display Technology
11.6.2.1.2. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Yeast Display Technology
11.6.2.1.3. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Other Display Technologies
11.6.2.2. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Distribution by Type of Molecule
11.6.2.2.1. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Antibodies
11.6.2.2.2. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Peptides
11.6.2.2.3. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Other Molecules

11.6.3. Display Library Technologies and Affiliated Services Market Opportunity in Asia-Pacific Across Key Market Segments, 2021-2030
11.6.3.1 Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Technology
11.6.3.1.1 Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Phage Display Technology
11.6.3.1.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Yeast Display Technology
11.6.3.1.3. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Other Display Technologies
11.6.3.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Molecule
11.6.3.2.1. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Antibodies
11.6.3.2.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Peptides
11.6.3.2.3. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Other Molecules

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Specifica
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Andrew Bradbury (CSO / Founder) and Ken Sharples (CEO / Founder)

13.3. YUMAB
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Thomas Schirrmann (CEO / General Manager)

13.4. Integral Molecular
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Benjamin J. Doranz (President and CEO)
13.5. ImmunoPrecise Antibodies 
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Debby Kruijsen (General Manager, ImmunoPrecise Antibodies, Europe)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1. Popular Display Library Technologies
Figure 3.2. Structure of a Bacteriophage
Figure 3.3. Phage Display Technique: Basic Steps
Figure 3.4. Construction of mRNA Display Technology
Figure 3.5. Construction of Bacterial Display Library
Figure 4.1. Phage Display Library Technologies and Affiliated Services: Type of Molecule Discovered
Figure 4.2. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
Figure 4.3. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Library
Figure 4.4. Phage Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
Figure 4.5. Phage Display Library Technologies and Affiliated Services: Distribution by Source Organism
Figure 4.6. Phage Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
Figure 4.7. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
Figure 4.8. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
Figure 4.9. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
Figure 4.10. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
Figure 5.1. Other Display Library Technologies and Affiliated Services: Distribution by Type of Molecule Discovered
Figure 5.2. Other Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
Figure 5.3. Other Display Library Technologies and Affiliated Services: Distribution by Type of Library
Figure 5.4. Other Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
Figure 5.5. Other Display Library Technologies and Affiliated Services: Distribution by Source Organism
Figure 5.6. Other Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
Figure 5.7. Other Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
Figure 5.8. Other Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
Figure 5.9. Other Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
Figure 5.10. Other Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
Figure 6.1. Creative Biolabs: Service Portfolio
Figure 6.2. ImmunoPrecise Antibodies: Service Portfolio
Figure 6.3. IONTAS: Service Portfolio
Figure 6.4. LakePharma: Service Portfolio
Figure 6.5. Leading Biology: Service Portfolio
Figure 6.6. Leading Biology: Premade Phage Display Antibody Libraries
Figure 6.7. Sino Biological: Service Portfolio
Figure 7.1. Biologics Discovered Using Phage Display Method: First Launch Timeline
Figure 7.2. Biologics Discovered Using Phage Display Method: Word Cloud Representation of Target Antigen / Gene
Figure 7.3. Biologics Discovered Using Phage Display Method: Distribution by Target Disease Indications and Therapeutic Area
Figure 7.4. Biologics Discovered Using Phage Display Method: Logo Landscape Highlighting Revenues Generated in 2020
Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Focus Area (Type of Molecule)
Figure 8.4. Partnerships and Collaborations: Distribution by Focus Area (Target Therapeutic Area)
Figure 8.5. Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6. Most Active Players: Distribution by Number of Partnerships
Figure 8.7. Partnerships and Collaborations: Distribution by Geography
Figure 8.8. Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 9.1. Publication Analysis: Cumulative Year-wise Trend, 2017-2021 (till March)
Figure 9.2. Publication Analysis: Distribution by Focus Area
Figure 9.3. Publication Analysis: Distribution by Type of Molecule
Figure 9.4. Publication Analysis: Word Cloud of Study Titles
Figure 9.5. Key Journals: Distribution by Number of Publications
Figure 10.1. Patent Analysis: Distribution by Type of Patent
Figure 10.2. Patent Analysis: Cumulative Distribution by Publication Year, 2017-2021 (till March)
Figure 10.3. Patent Analysis: Distribution by Type of Patent and Publication Year (till March)
Figure 10.4. Patent Analysis: Distribution by Geography
Figure 10.5. Patent Analysis: Distribution by Jurisdiction
Figure 10.6. Patent Analysis: Distribution by CPC Symbols
Figure 10.7. Patent Analysis: Emerging Focus Areas
Figure 10.8. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9. Leading Industry Players: Distribution by Number of Patents
Figure 10.10. Leading Players: Distribution by International Patents
Figure 10.11. Patent Analysis: Distribution of Patents by Age
Figure 10.12. Patent Analysis: Distribution of Patents by Geography, 2017-2021 (till March)
Figure 10.13. Display Library Technologies: Patent Valuation
Figure 11.1. Global Display Library Technologies and Affiliated Services Market (Focus on Hit Generation Services), 2021-2030 (USD Million)
Figure 11.2. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Type of Display Library Technology (USD Million)
Figure 11.3. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Type of Molecule (USD Million)
Figure 11.4. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Geography (USD Million)
Figure 11.5. Display Library Technologies and Affiliated Services Market in North America, 2021-2030 (USD Million)
Figure 11.6. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Phage Display Technology (USD Million)
Figure 11.7. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Yeast Display Technology (USD Million)
Figure 11.8. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Other Display Technologies (USD Million)
Figure 11.9. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Antibodies (USD Million)
Figure 11.10. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Peptides (USD Million)
Figure 11.11. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Other Molecules (USD Million)
Figure 11.12. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Phage Display Technology (USD Million)
Figure 11.13. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Yeast Display Technology (USD Million)
Figure 11.14. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Other Display Technologies (USD Million)
Figure 11.15. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Antibodies (USD Million)
Figure 11.16. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Peptides (USD Million)
Figure 11.17. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Other Molecules (USD Million)
Figure 11.18. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Phage Display Technology (USD Million)
Figure 11.19. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Yeast Display Technology (USD Million)
Figure 11.20. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Other Display Technologies (USD Million)
Figure 11.21. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Antibodies (USD Million)
Figure 11.22. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Peptides (USD Million)
Figure 11.23. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Other Molecules (USD Million)

List Of Tables

Table 4.1. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Developers, Type of Molecule Generated and Types of Antibodies Generated
Table 4.2. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Type of Library and Library Size / Complexity
Table 4.3. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Animal Model Use
Table 4.4. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Types of Services Offered
Table 4.5. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Companies Offering Drug Discovery Platform(s)
Table 4.6. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): List of Companies
Table 5.1. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Developer, Type of Molecule Generated and Type of Antibodies Generated
Table 5.2. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Type of Library and Library Size / Complexity
Table 5.3. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Animal Model Used
Table 5.4. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Types of Services Offered
Table 5.5. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Companies Offering Drug Discovery Platform(s)
Table 4.6. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): List of Companies
Table 6.1. Display Library Technologies and Affiliated Services: List of Companies Profiled
Table 6.2. Abzena: Company Snapshot
Table 6.3. Abzena: Recent Developments and Future Outlook
Table 6.4. Creative Biolabs: Company Snapshot
Table 6.5. Creative Biolabs: Recent Developments and Future Outlook
Table 6.6. Distributed Bio: Company Snapshot
Table 6.6. Distributed Bio: Recent Developments and Future Outlook
Table 6.7. ImmunoPrecise Antibodies: Company Snapshot
Table 6.8. ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 6.9. IONTAS: Company Snapshot
Table 6.10. IONTAS: Recent Developments and Future Outlook
Table 6.11. LakePharma: Company Snapshot
Table 6.12. LakePharma: Recent Developments and Future Outlook
Table 6.13. Leading Biology: Company Snapshot
Table 6.14. Sino Biological: Company Snapshot
Table 6.16. XOMA: Company Snapshot
Table 6.17. XOMA: Recent Developments and Future Outlook
Table 7.1. List of Approved Biologics Discovered Using Phage Display Method: Information on Launch Year, Target, Indication and Therapeutic Area
Table 7.2. List of Clinical Stage Biologics Discovered Using Phage Display Library Method
Table 8.1. Partnerships and Collaborations: Information on Year and Type, 2017-2021
Table 8.2. Partnerships and Collaborations: Information on Focus Area
Table 8.3. Partnerships and Collaborations: Information on Geography
Table 10.1. Display Library Technologies: Prominent CPC Codes
Table 10.2. Display Library Technologies: Most Popular CPC Symbols
Table 10.3. Display Library Technologies: List of Top CPC Symbols
Table 10.4. Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 10.5. Patent Analysis: List of Relatively High Value Patents
Table 14.1. Phage Display Library Technologies and Affiliated Services: Type of Molecule Discovered
Table 14.2. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
Table 14.3. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Library
Table 14.4. Phage Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
Table 14.5. Phage Display Library Technologies and Affiliated Services: Distribution by Animal Model Used
Table 14.6. Phage Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
Table 14.7. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
Table 14.8. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
Table 14.9. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
Table 14.10. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
Table 14.11. Other Display Library Technologies and Affiliated Services: Distribution by Type of Molecules Generated
Table 14.12. Other Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
Table 14.14. Other Display Library Technologies and Affiliated Services: Distribution by Type of Library
Table 14.14. Other Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
Table 14.15. Other Display Library Technologies and Affiliated Services: Distribution by Animal Model Used
Table 14.16. Other Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
Table 14.17. Other Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
Table 14.18. Other Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
Table 14.19. Other Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
Table 14.20. Other Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
Table 14.21. Biologics Discovered Using Phage Display Method: First Launch Year Timeline
Table 14.22. Biologics Discovered Using Phage Display Method: Distribution by Target Disease Indications and Therapeutic Area
Table 14.23. Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.24. Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.25. Partnerships and Collaborations: Distribution by Focus Area (Type of Molecule)
Table 14.26. Partnerships and Collaborations: Distribution by Focus Area (Target Therapeutic Area)
Table 14.27. Partnerships and Collaborations: Distribution by Type of Partner
Table 14.28. Most Active Players: Distribution by Number of Partnerships
Table 14.29. Partnerships and Collaborations: Distribution by Geography
Table 14.30. Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 14.31. Publication Analysis: Cumulative Year-wise Trend, 2017-2021 (till March)
Table 14.32. Publication Analysis: Distribution by Focus Area
Table 14.33. Publication Analysis: Distribution by Type of Molecule
Table 14.34. Key Journals: Distribution by Number of Publications
Table 14.35. Patent Analysis: Distribution by Type of Patent
Table 14.36. Patent Analysis: Cumulative Distribution by Publication Year, 2017-2021 (till March)
Table 14.37. Patent Analysis: Distribution by Type of Patent and Publication Year (till March)
Table 14.38. Patent Analysis: Distribution by Geography
Table 14.39. Patent Analysis: Distribution by Jurisdiction
Table 14.40. Patent Analysis: Distribution by CPC Symbols
Table 14.41. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 14.42. Leading Industry Players: Distribution by Number of Patents
Table 14.43. Leading Players: Distribution by International Patents
Table 14.44. Patent Analysis: Distribution of Patents by Age
Table 14.45. Patent Analysis: Distribution of Patents by Geography, 2017-2021 (till March)
Table 14.46. Display Library Technologies: Patent Valuation
Table 14.47. Global Display Library Technologies and Affiliated Services Market (Focus on Hit Generation Services), 2021-2030 (USD Million)
Table 14.48. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Type of Display Library Technology (USD Million)
Table 14.49. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Type of Molecule (USD Million)
Table 14.50. Display Library Technologies and Affiliated Services Market, 2021-2030: Distribution by Geography (USD Million)
Table 14.51. Display Library Technologies and Affiliated Services Market in North America, 2021-2030 (USD Million)
Table 14.52. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Phage Display Technology (USD Million)
Table 14.53. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Yeast Display Technology (USD Million)
Table 14.54. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Other Display Technologies (USD Million)
Table 14.55. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Antibodies (USD Million)
Table 14.56. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Peptides (USD Million)
Table 14.57. Display Library Technologies and Affiliated Services Market in North America, 2021-2030: Share of Other Molecules (USD Million)
Table 14.58. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Phage Display Technology (USD Million)
Table 14.59. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Yeast Display Technology (USD Million)
Table 14.60. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Other Display Technologies (USD Million)
Table 14.61. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Antibodies (USD Million)
Table 14.62. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Peptides (USD Million)
Table 14.63. Display Library Technologies and Affiliated Services Market in Europe, 2021-2030: Share of Other Molecules (USD Million)
Table 14.64. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Phage Display Technology (USD Million)
Table 14.65. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Yeast Display Technology (USD Million)
Table 14.66. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Other Display Technologies (USD Million)
Table 14.67. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Antibodies (USD Million)
Table 14.68. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Peptides (USD Million)
Table 14.69. Display Library Technologies and Affiliated Services Market in Asia-Pacific, 2021-2030: Share of Other Molecules (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. Ab Initio Biotherapeutics
  2. AbbVie
  3. Abcam
  4. AbCheck
  5. Abcore
  6. AbGenics Life Sciences 
  7. Abott 
  8. Abveris 
  9. Abwiz Bio
  10. Abzena 
  11. Abzyme Therapeutics 
  12. Adagene
  13. Adaptate Biotherapeutics
  14. AdipoGen Life Sciences
  15. Agenus
  16. AgonOx 
  17. Aldevron
  18. AlpaLife
  19. Alpha Lifetech
  20. Alphamab
  21. Amgen
  22. Anchor Ingredients
  23. Antibody Design Labs
  24. AP Biosciences
  25. AstraZeneca
  26. AtaGenix Laboratories 
  27. Athera Biotechnologies
  28. AvantGen
  29. BASF
  30. Baxter
  31. Bayer
  32. BeiGene
  33. Bicycle Therapeutics
  34. Bio Bench
  35. Biogen
  36. BioInvent
  37. Biologics International 
  38. Biomolecular Discovery Services
  39. Bio-Rad Laboratories
  40. Biosion 
  41. BIOTEM
  42. bluebird bio
  43. Bristol Myers Squibb
  44. Boehringer Ingelheim
  45. CALIXAR
  46. Cambridge Antibody Technology Group 
  47. Carterra
  48. Catalent 
  49. CDI Labs
  50. Celsius Therapeutics
  51. Charles River
  52. ChemPartner
  53. Chia Tai Tianqing Pharmaceutical Group
  54. Chugai Pharmaceutical
  55. Creative Biolabs
  56. Creative Diagnostics
  57. Crystal Bioscience
  58. CUSABIO
  59. Direct Flow Medical
  60. Distributed Bio
  61. Dyax
  62. Eli Lilly
  63. Elpis Biopharmaceuticals
  64. Epsilon Molecular Engineering 
  65. EVQLV
  66. Exelixis
  67. Exiris
  68. FairJourney Biologics
  69. Ferring Pharmaceuticals
  70. Genagon Therapeutics
  71. Gene Universal 
  72. GeneFrontier 
  73. Genentech
  74. GeNext Genomics
  75. GenoFocus
  76. GenScript
  77. GeoVax
  78. GlaxoSmithKline
  79. Glenmark Pharmaceuticals
  80. Iksuda Therapeutics (formerly known as Glythera)
  81. H3 Biomedicine 
  82. Harbour BioMed 
  83. HD Biosciences
  84. Hualan Genetic 
  85. Human Genome Sciences
  86. Hybrigenics Services
  87. i2 Pharmaceuticals
  88. Indiana Biosciences Research Institute (IBRI)
  89. Icagen
  90. Icosagen
  91. IGEM Therapeutics
  92. ImClone Systems 
  93. iMetabolic Biopharma
  94. Immatics Biotechnologies 
  95. Immune Biosolutions
  96. Immune Pharmaceuticals
  97. ImmunoPrecise Antibodies
  98. Innovent Biologics
  99. Inoterm
  100. IONTAS
  101. IRBM
  102. Janssen Pharmaceuticals 
  103. Johnson & Johnson
  104. Just-Evotech Biologics
  105. Kadmon
  106. Knoll
  107. KPC Pharmaceuticals
  108. LakePharma
  109. Leading Biology
  110. Ligand Pharmaceuticals
  111. MabGenesis
  112. MedImmune
  113. Merck
  114. Mereo BioPharma
  115. Merrimack
  116. Merus
  117. MeSCue-Janusys
  118. ModiQuest
  119. Molecular Templates
  120. Moradec
  121. MorphoSys
  122. Mount Sinai 
  123. Navigo Proteins
  124. Nbbiolab
  125. NeoClone 
  126. Novartis 
  127. NovImmmune
  128. Novozymes
  129. Oak BioSciences
  130. OncoMed Pharmaceuticals
  131. ONO PHARMACEUTICAL
  132. OriMAbs
  133. Ossianix
  134. OXGENE
  135. Pandion Therapeutics
  136. Pepscan
  137. Pfizer
  138. PharmAbcine
  139. Philogen
  140. ProMab Biotechnologies
  141. ProteoGenix
  142. QOOLABS
  143. Quell Therapeutics
  144. RePHAGEN
  145. Roche
  146. SangStat
  147. Sanofi
  148. Sarepta Therapeutics (formerly known as AVI BioPharma)
  149. Scholar Rock 
  150. Schrödinger
  151. Scotia Biologics
  152. Sea Lane Biotechnologies
  153. EMD Serono (Acquired by Merck)
  154. Sino Biological
  155. Specifica 
  156. Sungwun Bio
  157. Surface Oncology
  158. Syd Labs
  159. Synbio Technologies
  160. Syngene International
  161. Takeda
  162. Tanabe Research Laboratories
  163. Taurus Biosciences (Acquired by Ligand Pharmaceuticals)
  164. TetraGenetics
  165. The University of Texas MD Anderson Cancer Center
  166. Tizona Therapeutics
  167. Torch Biosciences
  168. Transgene
  169. Twist Bioscience
  170. UCB
  171. University of California 
  172. University of Pennsylvania 
  173. venBio Partners
  174. VicuTec Biologicals 
  175. Vir Biotechnology
  176. Viva Biotech
  177. WuXi Biologics
  178. xCella Biosciences
  179. XOMA
  180. Y-Biologics
  181. YUMAB
  182. Yurogen Biosystems
  183. Zumotor Biologics

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com